Aetna does not cover the Shield blood test for colorectal cancer screening. The insurer’s Medical Clinical Policy Bulletin 0516 lists the Guardant Shield test as experimental, investigational, or unproven, which means claims for the test will be denied under standard Aetna plans.1Aetna. Colonoscopy, Colorectal Cancer Screening, and Related Procedures If you want the test, you will generally pay out of pocket, appeal the denial, or choose a different screening method that Aetna does cover.
Why Aetna Calls Shield Experimental
Aetna’s bulletin states plainly that the test’s effectiveness “has not been established.”1Aetna. Colonoscopy, Colorectal Cancer Screening, and Related Procedures That label is the insurer’s standard way of describing procedures it does not believe have enough evidence behind them for routine coverage.
The reason that label matters so much comes down to one agency: the U.S. Preventive Services Task Force. The USPSTF’s current colorectal cancer screening recommendation, last updated in May 2021, excludes blood-based tests, citing limited evidence and the availability of other effective screening methods.2U.S. Preventive Services Task Force. Colorectal Cancer Screening Under the Affordable Care Act, commercial plans must cover preventive services the USPSTF rates “A” or “B” with no cost sharing.3Centers for Medicare & Medicaid Services. ACA Implementation FAQs Part XII Shield has no USPSTF rating at all, so no federal mandate forces Aetna to pay for it.
An updated recommendation that might change this is not close. The USPSTF has not met in over a year, and five member seats that expired in December remain unfilled.4Medical Economics. Updated Colorectal Cancer Screening Includes Blood Tests, At-Home Options
Why Recent Guideline Endorsements Haven’t Changed Aetna’s Position
You may have read that Shield is now in major clinical guidelines. That is accurate but incomplete. The National Comprehensive Cancer Network added Shield to its colorectal cancer screening guidelines in mid-2025, recommending it every three years for average-risk adults 45 and older.5Guardant Health. NCCN Updates Colorectal Cancer Screening Guidelines to Include Shield On May 27, 2026, the American Cancer Society updated its guidelines to include blood-based screening, naming Shield.6American Cancer Society. Colorectal Cancer Screening Guideline Update 2026
Neither endorsement is strong. The ACS labeled blood-based tests “not preferred” and recommended them only for patients who decline or cannot complete stool-based tests or colonoscopy.7CA: A Cancer Journal for Clinicians. Colorectal Cancer Screening: An Update to the American Cancer Society Guideline, 2026 The ACS also cited Shield’s lower sensitivity for early-stage cancers and precancerous polyps.6American Cancer Society. Colorectal Cancer Screening Guideline Update 2026
Aetna’s clinical policy bulletin shows no sign of updating in response.1Aetna. Colonoscopy, Colorectal Cancer Screening, and Related Procedures NCCN and ACS guidelines can influence insurers over time, but they do not carry the ACA weight that a USPSTF recommendation would. Other large commercial insurers have taken the same stance: Blue Cross Blue Shield of Texas lists Shield as “not reimbursable,”8Blue Cross Blue Shield of Texas. Lab Management Program Policy and Blue Shield of California classifies blood-based biomarker tests for colorectal cancer as investigational.9Blue Shield of California. Oncology Cancer Screening Medical Policy
A note on Medicare, because the two often get confused. Medicare covers Shield under National Coverage Determination 210.3 once every three years, with $0 out of pocket for Fee for Service beneficiaries.10Guardant Health. Shield Blood Test Now Commercially Available in U.S. That coverage does not extend to commercial Aetna plans. If you have an Aetna Medicare Advantage plan, benefits may differ from commercial Aetna, and you should check your specific plan documents or call the number on your card.
What You’ll Pay Out of Pocket
Guardant Health, the maker of Shield, is direct about this: “Patients not covered by Medicare may have an out-of-pocket cost.”11Guardant Health. Coverage and Support The cash-pay rate for the test is $1,495 as of August 2024.12Guardant Health. Patient Coverage and Support
Guardant runs a support program called Guardant Access that evaluates patients for financial assistance, helps navigate billing, and manages claims.13Guardant Health. For Patients Shield-specific help is available at 1-855-722-7335 or ScreeningBilling@GuardantHealth.com.12Guardant Health. Patient Coverage and Support
How to Appeal an Aetna Denial
You can appeal a Shield denial, though the odds of overturning it are uncertain given the test’s current standing with the USPSTF. The process starts by calling Member Services or submitting a written complaint and appeal form within 180 days of the denial notice.14Aetna. Claim Denials
Your doctor can also request a peer-to-peer review with an Aetna clinician and present clinical evidence for why the test is medically appropriate.15Aetna. Dispute Process Aetna suggests supporting an appeal with peer-reviewed literature. The NCCN and ACS inclusions, plus Shield’s FDA approval in July 2024,16U.S. Food and Drug Administration. Shield (P230009) are the evidence most likely to be cited.
If internal appeals fail, most members have the right to request an independent external review. That option is particularly relevant when a denial is based on experimental or investigational status.17Aetna. Disputes and Appeals Overview
Covered Screening Alternatives
Aetna covers the standard colorectal cancer screening methods: colonoscopy, stool-based tests including FIT and Cologuard, flexible sigmoidoscopy, and CT colonography.1Aetna. Colonoscopy, Colorectal Cancer Screening, and Related Procedures Under the ACA, these are typically covered without cost-sharing when done as preventive screenings in network.18Aetna. Preventive Care Coverage
These covered options also perform better on the measure that matters most for prevention. Colonoscopy can find and remove polyps in one procedure. Stool-based Cologuard detects about 42% of precancerous polyps, while Shield detects about 13%.19Memorial Sloan Kettering Cancer Center. Is Shield a Good Colorectal Cancer Screening Blood Test A positive Shield result also requires a follow-up colonoscopy to confirm, so for most patients a covered test is both cheaper and more thorough.